Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quigley sales

This article was originally published in The Tan Sheet

Executive Summary

Cold-Eeze marketer spent $714,329 on cooperative advertising promotions during third quarter ended Sept. 30, more than triple the level spent in the year-ago period, 1Quigley's 10-Q says. Net sales rose 19.2% to $8.3 mil., with a net loss of $500,395, compared to net income of $313,615 in the year-ago period. Quigley is partnering with CDC to include educational materials about appropriate antibiotic use in Cold-Eeze samples sent to 7,000-8,000 healthcare providers by year end. Firm also intends to introduce one Cold-Eeze line extension in March 2003; honey lemon-flavored zinc lozenge, the line's most recent addition, began shipping in August (2"The Tan Sheet" Feb. 25, 2002, In Brief)...

You may also be interested in...



Quigley “eezes” into profitability

Cold-Eeze marketer will add honey lemon flavor to zinc lozenge line in time for next cold season, firm says Feb. 19. All Cold-Eeze products will be promoted in the fall with six-week radio ad campaign; Quigley says it has shifted emphasis from broad-based media campaigns to more "efficient" programs, to which firm attributes recent strong earnings growth. For the year, Quigley reported revenues up 46.8% to $24.7 mil., with net income of $216,000 compared with a $5.2 mil. loss last year. Q4 revenue rose 19.7% to $8.5 mil.; net income inched up 2.7%...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094776

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel